Tempus’ Solid Tumor CDx Test Gets Breakthrough Device Designation
The U.S. FDA has granted Tempus Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test for solid tumors.
Read More
Search Results for: lung cancer
Partnership Aims to Improve OncoPrism Predictive Diagnostic
Culmination Bio and Cofactor Genomics are partnering to leverage biobank samples and data to develop the OncoPrism test for 11 cancers.
Read More
Results of Study to Evaluate Grail’s MCED Test Announced
The analysis showed strong performance of Grail’s MCED methylation-based platform in the symptomatic population of more than 6,000 patients
Read More
Labcorp Plasma Focus Liquid Biopsy Test Launches
Labcorp has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for solid tumors.
Read More
How Will Generalist Medical AI Change Diagnostics, Medicine?
Generalist medical AI models can integrate multiple data types — such as MRI scans, X-rays, blood test results, medical texts, and genomic testing — to perform a range of tasks
Read More